Literature DB >> 27994603

Fibroblast Growth Factor 23 and Hypophosphatemia: A Case of Hypophosphatemia along the Rickets-Osteomalacia Spectrum.

George T Georges1, O Nájera1, Kurt Sowers2, James R Sowers3.   

Abstract

Phosphorus is a key component of bone, and a deficiency results in poor mineralization along with other systemic symptoms of hypophosphatemia. Various causes of hypophosphatemia with renal wasting of phosphorus have been identified. These include the Fanconi syndrome, various genetic mutations of fibroblast growth factor 23 (FGF23) handling and the sodium/phosphate cotransporter, and those due to FGF23 secretion by mesenchymal tumors. Depending on the cause, vitamin D metabolism may also be impaired, which may amplify the deficiency in phosphorus and render treatment more challenging. Here, we report a case of hypophosphatemia and multiple stress fractures in a 20-year-old male college student living with chronic bone pain and anxiety about suffering further fractures. We further review the literature regarding this spectrum.

Entities:  

Keywords:  Fibroblast growth factor 23; Osteomalacia; Phosphorus

Year:  2016        PMID: 27994603      PMCID: PMC5159715          DOI: 10.1159/000449476

Source DB:  PubMed          Journal:  Cardiorenal Med        ISSN: 1664-5502            Impact factor:   2.041


  16 in total

Review 1.  Renal phosphate transporters.

Authors:  Eleanor Lederer
Journal:  Curr Opin Nephrol Hypertens       Date:  2014-09       Impact factor: 2.894

Review 2.  Cutaneous skeletal hypophosphatemia syndrome: clinical spectrum, natural history, and treatment.

Authors:  D Ovejero; Y H Lim; A M Boyce; R I Gafni; E McCarthy; T A Nguyen; L F Eichenfield; C M C DeKlotz; L C Guthrie; L L Tosi; P S Thornton; K A Choate; M T Collins
Journal:  Osteoporos Int       Date:  2016-08-06       Impact factor: 4.507

3.  Approach to the hypophosphatemic patient.

Authors:  Erik A Imel; Michael J Econs
Journal:  J Clin Endocrinol Metab       Date:  2012-03       Impact factor: 5.958

4.  Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D.

Authors:  Shiguang Liu; Wen Tang; Jianping Zhou; Jason R Stubbs; Qiang Luo; Min Pi; L Darryl Quarles
Journal:  J Am Soc Nephrol       Date:  2006-04-05       Impact factor: 10.121

5.  Hereditary hypophosphatemic rickets with hypercalciuria is caused by mutations in the sodium-phosphate cotransporter gene SLC34A3.

Authors:  Bettina Lorenz-Depiereux; Anna Benet-Pages; Gertrud Eckstein; Yardena Tenenbaum-Rakover; Janine Wagenstaller; Dov Tiosano; Ruth Gershoni-Baruch; Norbert Albers; Peter Lichtner; Dirk Schnabel; Ze'ev Hochberg; Tim M Strom
Journal:  Am J Hum Genet       Date:  2005-12-09       Impact factor: 11.025

6.  Phosphate Metabolism in Cardiorenal Metabolic Disease.

Authors:  Deepashree Gupta; Stephen Brietzke; M R Hayden; L Romayne Kurukulasuriya; James R Sowers
Journal:  Cardiorenal Med       Date:  2011-10-13       Impact factor: 2.041

7.  Serum FGF23 levels in normal and disordered phosphorus homeostasis.

Authors:  Thomas J Weber; Shiguang Liu; Olafur S Indridason; L Darryl Quarles
Journal:  J Bone Miner Res       Date:  2003-07       Impact factor: 6.741

Review 8.  The wrickkened pathways of FGF23, MEPE and PHEX.

Authors:  Peter S N Rowe
Journal:  Crit Rev Oral Biol Med       Date:  2004-09-01

Review 9.  Genetic disorders of phosphate regulation.

Authors:  Jyothsna Gattineni; Michel Baum
Journal:  Pediatr Nephrol       Date:  2012-02-14       Impact factor: 3.714

10.  Therapeutic management of hypophosphatemic rickets from infancy to adulthood.

Authors:  Agnès Linglart; Martin Biosse-Duplan; Karine Briot; Catherine Chaussain; Laure Esterle; Séverine Guillaume-Czitrom; Peter Kamenicky; Jerome Nevoux; Dominique Prié; Anya Rothenbuhler; Philippe Wicart; Pol Harvengt
Journal:  Endocr Connect       Date:  2014-03-14       Impact factor: 3.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.